1Zink A, Braun J, Listing J, et al. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: results from the German rheumatological database. J Rheumatol, 2000, 27: 613- 622.
2Shealy DJ, Wooley PH, Emmell E, et al. Anti-TNF-α antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res, 2002, 4(5): R7.
3Feldmann M, Brennan FM, Maini RN. The role of cytokines in rheumatoid arthritis. Ann Rev Im munol, 1996, 14: 396-440.
4Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol, 1994, 21: 2286-2291.
5Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J Rheumatol, 1994, 21: 2281-2285.
6Mander M, Simpson JM, McLellan A, et al. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis, 1987, 46: 197-202.
7Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS metrology index. J Rheumatol, 1994, 21: 1694-1698.
8Anderson J J, Baron G, Van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum, 2001, 44: 1876-1886.
9Bran& J, Khariouzov A, Listing J, et al. Six-month results of a double blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum,2003, 48: 1667-1675.
10Davis JC, Van Der Heijide D, Braun J, et al. Recominant human tumor necrosis factor receptor (etanercept) for treating ankylosing: a randomized, controlled trial. Arthritis Rheum, 2003, 48: 3230-3236.
3Smolen JS,Landewe R,Breedveld FC,et al. EULAR recomenda- tion for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis,2010, 69:964-975.
4Feldmann M, Brennan FM, Maini RN. The role of cytokines in rheumatoid arthritis. Ann Rev Immunol, 1996,14: 397-440.
5Aruett FC,Edworthy SM,Bloch DA,et al The American Rheumatism Association 1987 revised criteria for the classifica- tion of rheumatoid arthritis. Arthritis Rheum, 1988,31 : 315-324.
6Hochberg MC,Chang RW,Dwosh I,et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid asthritis. Arthritis Rheum, 1992,35 : 498-502.
7Firestein GS,Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis. N Engl J Med, 1997,337 : 195-197.
8Haseeb A, Haqqi TM. Immunopathogenesis of osteoarthritis [ J ]. Clin Immuno1,2013,146 ( 3 ) : 185 - 196.
9B61int G, Szebenyi B. Diagnosis of osteoarthritis. Guidelines and current pitfalls[ J]. Drugs, 1996,52 Suppl 3 : 1 - 13.
10Deirmengian CA, Lonner JH. What s new in adult recon- structive knee surgery[J]. J Bone Joint Surg Am,2013,95 (2) :184 - 190.
